Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News


Weekly Extractions featuring Atai and Field Trip

In this edition of Weekly Extractions, host Adam Tubero updates us on everything that has happened recently in the world of psychedelic companies and stocks. This episode specifically features updates on $ATAI and $FTRP. Watch the video below for all of the details. Please like, share, comment, and subscribe on YouTube. There will be plenty…


FSD Pharma Inc. Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics…

Irwin Naturals Press

Irwin Naturals Acquires Ketamine Media

Irwin Naturals Inc. (CSE: IWIN / OTC: IWINF / FRA: 97X) is thrilled to announce the successful acquisition of Keta Media, LLC, dba Ketamine Media (“Ketamine Media”) as of March 17, 2023. Ketamine Media is the nation’s foremost advertising company dedicated to raising awareness about the clinical use of ketamine. The agreement with Ketamine Media was initially…

Atai Press

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights. “With multiple clinical-stage programs aimed at addressing significant unmet patient needs in mental health and the capital to fund us into the first half…

Psyence Press

Psyence Group Announces Cantheon Capital Private Placement

Psyence Group Inc (CSE: PSYG / OTCQB: PYSGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that it has entered into a brokered subscription agreement with Cantheon Capital, LLC (“Cantheon”). Cantheon, a fund focussed on listed biotech stocks with near term catalysts, will…

Field Trip Health Ltd. Press

Field Trip Health & Wellness Obtains CCAA Protection

Field Trip Health & Wellness Ltd. (TSX-V: FTHW) today announced that it has obtained an Order (the “Initial Order”) for creditor protection from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). PricewaterhouseCoopers Inc. has been appointed as the CCAA monitor (the “Monitor”). After careful consideration of the…

BetterLife Pharma Press

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, in its March 17, 2023 issue, Medical Xpress, has published an article titled “Study hints at the promise of non-hallucinogenic LSD for treating mood disorders,” which is based on BetterLife’s…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.